Propelling the Future of Medicine
Arvinas (arvinas.com) scores 80 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 72nd percentile of 14032 Healthcare brands.
Arvinas is a clinical-stage biotechnology company headquartered in New Haven, United States, founded in 2013. The company develops targeted protein degradation therapeutics using its proprietary PROTAC protein degrader technology. Arvinas focuses on advancing this novel drug discovery platform from preclinical research into clinical development to address serious diseases with unmet medical needs, serving patients, healthcare providers, biopharmaceutical partners, and investors.
| Brand Name | Arvinas |
|---|---|
| Domain | arvinas.com |
| Industry | Healthcare |
| Founded | 2013 |
| Headquarters | New Haven |
| Main Competitors | Kymera Therapeutics (76/100), C4 Therapeutics (73/100), Nurix Therapeutics (73/100), Monte Rosa Therapeutics (76/100), Cullgen |
Moz Domain Authority 46/100 vs category average 41 / leader 97 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #920,029 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics." (Meta description: 14 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Arvinas?", Claude could identify the brand as of September 2026. Arvinas is a clinical-stage biopharmaceutical company known for pioneering PROTAC (proteolysis targeting chimera) protein degrader technology, which uses the body's own ubiquitin-proteasome system to destroy disease-causing proteins rather than just inhibiting them. Its lead prog Best known for Inventing and leading development of PROTAC protein degrader drugs, notably ARV-471 for breast cancer.
When asked "Best brands similar to Arvinas?", Claude would recommend Arvinas as of September 2026. It's a leading and widely recognized name in targeted protein degradation, a novel and important therapeutic modality, so it would come up naturally in discussions of innovative biotech platforms.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Arvinas's main competitors in Healthcare: Kymera Therapeutics (76/100), C4 Therapeutics (73/100), Nurix Therapeutics (73/100), Monte Rosa Therapeutics (76/100).
Sources: Brand Analyzer scan
Arvinas is a clinical-stage biotechnology company based in New Haven, United States, founded in 2013. It specializes in developing targeted protein degradation therapeutics, an emerging class of medicines designed to address diseases that are difficult to treat with conventional drugs.
Sources: Arvinas official site
Arvinas has limited AI-search visibility, scoring 37/100 on Brand Analyzer's AI visibility composite (visibility 26, trust 40, recommendation 53). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Arvinas official site
Arvinas was founded in 2013. Arvinas operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Arvinas is headquartered in New Haven. Arvinas operates in the Healthcare category.
Sources: Wikidata
Arvinas develops medicines based on targeted protein degradation, using its proprietary PROTAC protein degrader technology. The company advances this platform from preclinical research through clinical development, aiming to create a new class of therapeutics for patients with serious diseases and unmet medical needs.
Sources: Arvinas official site
Arvinas scores 53/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Arvinas official site
Arvinas offers targeted protein degradation therapeutics developed through its PROTAC protein degrader technology platform. These are investigational medicines currently in clinical development stages, designed to address serious diseases through a novel drug discovery mechanism distinct from conventional pharmaceuticals.
Sources: Arvinas official site
Arvinas is known for pioneering PROTAC (proteolysis-targeting chimera) protein degrader technology, positioning itself as a leader in the emerging field of targeted protein degradation within clinical-stage biotechnology.
Sources: Arvinas official site
Arvinas can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Arvinas official site
Arvinas's work is relevant to patients with serious diseases who may benefit from its therapeutics, healthcare providers who may administer these treatments, biopharmaceutical partners collaborating on drug development, and investors interested in innovative protein degradation technology.
Sources: Arvinas official site
Arvinas scores 37/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Arvinas has a weak AI-visibility profile at 37/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (53/100) and its weakest is visibility (26/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #920,029 (Tranco) and a Moz Domain Authority of 46/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Arvinas from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Arvinas: Arkopharma (80/100), arcenciel (80/100), ARxIUM (80/100), American Society of Clinical Oncology (ASCO) (80/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.